Neurocrine Biosciences (NASDAQ:NBIX) Director Sells $590,588.10 in Stock

Posted by Brenda Bartman on May 14th, 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) Director Leslie Norwalk sold 3,810 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $155.01, for a total transaction of $590,588.10. Following the transaction, the director owned 2,429 shares in the company, valued at approximately $376,519.29. The trade was a 61.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Performance

NBIX traded down $2.27 during trading on Thursday, reaching $159.05. 1,285,154 shares of the stock were exchanged, compared to its average volume of 1,181,626. The stock has a market cap of $15.99 billion, a P/E ratio of 24.51, a price-to-earnings-growth ratio of 1.17 and a beta of 0.34. Neurocrine Biosciences, Inc. has a twelve month low of $117.40 and a twelve month high of $162.39. The stock’s 50 day moving average price is $132.99 and its two-hundred day moving average price is $138.21.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last issued its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The firm had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a return on equity of 19.79% and a net margin of 21.55%.Neurocrine Biosciences’s quarterly revenue was up 28.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.69 earnings per share. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 7.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently modified their holdings of NBIX. AQR Capital Management LLC lifted its position in Neurocrine Biosciences by 83.7% during the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after purchasing an additional 1,263,633 shares during the period. Norges Bank bought a new stake in Neurocrine Biosciences during the fourth quarter worth about $162,664,000. UBS Group AG lifted its position in Neurocrine Biosciences by 169.8% during the fourth quarter. UBS Group AG now owns 983,528 shares of the company’s stock worth $139,494,000 after purchasing an additional 618,956 shares during the period. First Trust Advisors LP lifted its position in Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock worth $126,367,000 after purchasing an additional 472,408 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Neurocrine Biosciences by 11.0% during the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after purchasing an additional 468,405 shares during the period. Institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on NBIX. Guggenheim restated a “buy” rating and set a $175.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, May 6th. Zacks Research upgraded shares of Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 15th. Truist Financial upped their price objective on shares of Neurocrine Biosciences from $140.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Wells Fargo & Company decreased their price objective on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Finally, Wedbush upped their price objective on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $184.15.

View Our Latest Stock Report on NBIX

Neurocrine Biosciences Company Profile

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.